However, in contrast with its negative regulatory role in T-cell responses, increasing evidence suggests that VISTA expression on TCs or ICs correlates with improved survival among patients with ovarian, cervical cancer, and endometrial cancer. Here, VSIR is linked to endometrial cancer.